Skyrocketing Prices: The Surging Cost of a Discontinued Medication

In a shocking turn of events, the price of a well-known medication for hemorrhoids, known as "Taining" or "Taining," has surged nearly tenfold after being discontinued for six months. This exorbitant price increase has caught the attention of social media platforms and sparked discussions about the impact on patients in need. 

The Discontinuation and Price Surge:

Taining, a popular Western medicine manufactured exclusively by Xi'an Yangsen, gained significant traction in the domestic hemorrhoid market and ranked among the top five selling products. However, due to the unavailability of sustainable raw materials, specifically the primary active ingredient, natural extract compound ruscogenin, Xi'an Yangsen decided to halt the supply of Taining and submitted a market withdrawal application to the National Medical Products Administration in October 2023.

Following the discontinuation, Taining's price has skyrocketed. Online reports indicate that the medication, which was previously priced at a modest 22.5 yuan per box, now commands a staggering 398 yuan per box. The price surge, estimated to be around tenfold, has left patients in shock and raised concerns about the affordability of essential medications.

Impact on the Hemorrhoid Medication Market:

With a rising number of individuals suffering from hemorrhoids and related anal conditions in China, the demand for hemorrhoid medications has been steadily increasing. Recent epidemiological surveys reveal that the prevalence of anal diseases among Chinese adults is as high as 51.14%, with 98.09% of these cases presenting symptoms of hemorrhoids. It is therefore no surprise that the hemorrhoid medication market has experienced substantial growth, with market size projected to reach 49.73 billion yuan by 2022.

The withdrawal of Taining from the market has created a void that other medications must fill. Ma Yinglong Musk Hemorrhoids Ointment, often hailed as the leader in the hemorrhoid medication market, has become the focus of consumer hopes and expectations. Investors have inquired whether Ma Yinglong has plans to produce a substitute for Taining, such as a compound ruscogenin suppository or cream, to capture the market share previously held by Xi'an Yangsen. However, the company has responded that it currently has no such plans.

Price Surge Phenomenon:

Price fluctuations and increases are not uncommon in the pharmaceutical industry. The supply-demand dynamics play a crucial role, and when key active ingredients are derived from non-renewable natural sources, shortages or price hikes can occur. Xi'an Yangsen, as the manufacturer of Taining, has stated that they do not intervene in the pricing decisions made by distributors or retailers, including the retail price. It is not unexpected for distributors to raise prices in response to tightened supply and demand conditions. In fact, other well-established pharmaceutical brands, such as Tongrentang, Guangyuyuan, Pien Tze Huang, Dong'e Ejiao, and Foci Pharmaceuticals, have previously announced price increases for their flagship products.

The abrupt discontinuation of Taining, coupled with the subsequent surge in its price, has shed light on the challenges faced by both patients and pharmaceutical companies. The soaring cost of essential medications raises concerns about accessibility and affordability for individuals in need. As the hemorrhoid medication market adapts to the absence of Taining, industry players will need to explore alternative solutions to meet the growing demand. It remains to be seen how the market will evolve in the face of these unprecedented developments, but one thing is certain: the impact of the discontinued medication and its exorbitant price surge will have far-reaching consequences for patients and the healthcare industry as a whole.